When administered concurrently with sedatives, Valocordin® may enhance their sedative effect. Сoncomitant administration of Valocordin® and neuroleptic agents and antianxiety agents enhances the effects of each of the drug ingredients; concurrent use of the product and central nervous system stimulants suppresses the effects of each of the drug ingredients. Alcohol enhances the effects of Valocordin® and may increase its toxicity. Phenobarbital contained in Valocordin® may induce liver enzymes, and this makes its concurrent use with drugs that are metabolized in the liver undesirable, as their concentration and consequent efficacy decrease as a result of accelerated metabolism (indirect anticoagulants, antibiotics, sulfonamides, etc.).
Pharmaceutical products containing valproinic acid enhance the effect of barbiturates.
Valocordin® contains phenobarbital, therefore, concomitant administration of this product and coumarin derivatives, griseofulvin, glucocorticoids, or oral contraceptives may lead to adverse interaction in the form of accelerated reduction of the effects of the above drugs.
It enhances the toxicity of pharmaceutical products containing methotrexate.